Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2024
Compliance Certificate under regulation 7(3) of SEBI (LODR) 2015 for the year ended 31st March 2024. Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 40(10) For The Year Ended 31St March, 2024
Submission of compliance certificate for the year ended 31st March 2024 issued by the Practicing Company Secretary. Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window
Closure of Trading Window for the quarter and year ended 31st March 2024 Suven Pharmaceuticals Ltd - 543064 - Intimation Regarding Shifting Of Registered Office From Hyderabad In The State Of Telangana To Mumbai In The State Of Maharashtra
Intimation regarding shifting of registered office from Hyderabad in the State of Telangana to Mumbai in the State of Maharashtra Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company will be conducting an Analyst Day in Hyderabad on 27th March 2024 wherein the management will be interacting with a group of analysts. No unpublished price-sensitive information will be shared during this interaction. This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI LODR, we wish to intimate you that the CRISIL has assigned the ratings as mentioned in the enclosed letter for the bank facilities of our company. Suven Pharmaceuticals Ltd - 543064 - Transcript Of Conference Call
Please find enclosed the transcript of the conference call held on 5th March 2024 Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to the proposed merger and the business outlook conference call intimation dated February 29, 2024, the audio recording of the conference call held on Tuesday, March 05, 2024.
Suven Pharmaceuticals Management Call: Merger Discussion
Conference Call with Suven Pharmaceuticals Management and Analysts to discuss the merger with Cohance Lifesciences and the business outlook for the combined entity. Listen to the full earnings transcript. Management in attendance: Annaswamy Vaidheesh, Dr. V Prasada Raju, and senior team. Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd & Others